NTRK1 and early-onset autosomal dominant Alzheimer disease: To the contrary,a recent review highlights the considerable potential of Trk PAMsas therapeutics for Alzheimer’s disease., Further, some of the compounds shown in Figure  were not emphatically described as Trk agonists.Instead, our points are these.